Previous Article | Next Article ![]()
Infection and Immunity, October 2000, p. 6052-6055, Vol. 68, No. 10
Department of Microbiology, Immunology, and
Parasitology, Louisiana State University Health Sciences
Center,1 and the Department of
Ophthalmology, Louisiana State University Eye
Center,2 New Orleans, Louisiana
Received 17 April 2000/Returned for modification 10 July
2000/Accepted 27 July 2000
Alpha-toxin is a major virulence factor in Staphylococcus
aureus keratitis. Active or passive immunization with alpha-toxin toxoid could protect against corneal damage. Results show that either
form of immunization did not kill bacteria but did significantly protect against corneal pathology, especially epithelial erosion.
Staphylococcus aureus is
the leading cause of human corneal infection that may result in loss of
visual acuity and blindness (3). Alpha-toxin is produced by
approximately 75% of S. aureus strains (2, 8,
25) and has been shown to be the major virulence factor in
Staphylococcus keratitis (6, 21). Considering the
importance of alpha-toxin in S. aureus keratitis, we
examined the effect of passively administered antibody to alpha-toxin
and active immunization with alpha-toxin toxoid in a rabbit
Staphylococcus keratitis model.
S. aureus strain 8325-4, an alpha-toxin-producing strain
previously analyzed in the rabbit keratitis model (6, 21),
was grown to log phase and diluted in tryptic soy broth (Difco
Laboratories, Inc., Detroit, Mich.). Alpha-toxin (Sigma, St. Louis,
Mo.) purity was determined by the presence of a single band at 33 kDa
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(20). Toxin was heat inactivated (80°C for 2 h) as
confirmed by a loss in hemolytic activity (4, 21).
New Zealand White rabbits (2.0 to 3.0 kg; Myrtle Rabbitry, Thompson
Station, Tenn.) were maintained in strict accordance with institutional
guidelines and the Guide for the Care and Use of Laboratory
Animals (13a). Rabbits were anesthetized as described previously (6, 20, 21). For passive immunization, bacteria were mixed (1:1, volume) with either preimmune rabbit sera or rabbit
sera containing antibody to alpha-toxin. Each cornea was intrastromally
injected with 20 µl of the bacteria-antibody mixture containing
approximately 100 CFU per cornea (6, 21). Immune sera mixed
with tryptic soy broth (1:1, 20 µl) were injected into rabbit corneas
to determine if the sera induced ocular inflammation. All rabbits were
slit lamp examined (SLE) from 10 h postinfection (p.i.) every
5 h until time of sacrifice. SLE of rabbit eyes was performed by
two masked observers (6, 20, 21). Corneal erosions were
detected using fluorescein, and diameters were measured and expressed
in millimeters.
Prior to experimentation, the sera of all rabbits were tested by
enzyme-linked immunosorbent assay (ELISA) to ensure the absence of
preexisting antibody to S. aureus alpha-toxin
(5). Specific-pathogen-free rabbits (n = 15)
were found to lack serum antibody to alpha-toxin. For active
immunization, rabbits (n = 4) were subcutaneously
injected with 50 µg of alpha-toxin toxoid mixed with complete
Freund's adjuvant (CFA; Sigma) once a month over a 3-month period.
Control rabbits (n = 4) were injected with CFA alone.
Four weeks following each immunization, sera and tears were collected.
Sera were assayed by ELISA for alpha-toxin-specific total antibody or
immunoglobulin G (IgG) antibody, using as secondary antibody either
anti-rabbit IgG or anti-rabbit gamma heavy chain, respectively. Total
antibody and IgA antibody to alpha-toxin in tears were assayed. Sera
with IgG titers of 5,000 caused neither agglutination of S. aureus nor inhibition of its growth in vitro (data not shown).
Once the serum total antibody titer (as measured by ELISA) to
alpha-toxin reached 5,000, the corneas were injected intrastromally with approximately 100 CFU of S. aureus 8325-4 (10 µl).
Rabbits were sacrificed when the SLE score reached 17 or at 45 h
p.i.
The number of viable S. aureus organisms per cornea was
determined by culturing dilutions of corneal homogenates in triplicate (6, 21). Data were analyzed statistically as described
previously (6, 21, 26). P values of To analyze the protectiveness of passive immunization, serum containing
IgG antibody to alpha-toxin (prepared as described above for active
immunization) was administered at the time of infection. Passive
immunization provided protection to the cornea as evidenced by
significantly lower SLE scores for the antibody-treated group than for
the control group at 20 and 25 h p.i. (P
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Immunization with Alpha-Toxin Toxoid Protects the
Cornea against Tissue Damage during Experimental Staphylococcus
aureus Keratitis
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
0.05
were considered significant.
0.0135) (Fig. 1). Erosions developed
at 15 h p.i. in only 25% of antibody-treated eyes whereas 75% of
eyes treated with preimmune sera developed erosions. There was no
difference in the numbers of bacteria recovered from both groups at
15 h p.i. (immunized = 5.61 ± 0.21 and control = 5.33 ± 0.29 log CFU/cornea; P = 0.492). The
erosions at 20 and 25 h p.i. were also significantly smaller in
antibody-treated eyes than in the eyes of rabbits treated with
preimmune sera (P
0.041) (Fig.
2).

View larger version (22K):
[in a new window]
FIG. 1.
SLE scores of passively immunized and control rabbits
during Staphylococcus keratitis. Bacteria were mixed with
either immune or preimmune sera at a 1:1 ratio, and the corneas
(n = 4) were injected with 20 µl of the
serum-bacteria mixture. A control group consisting of corneas injected
only with immune sera was also included. Eyes injected with bacteria
and immune sera had significantly lower SLE scores at 20 and 25 h
p.i. than eyes injected with bacteria and preimmune sera. Each asterisk
denotes a significant difference between groups receiving immune and
preimmune sera (P
0.0135). Data are expressed as
mean SLE ± the standard error of the mean (SEM).

View larger version (20K):
[in a new window]
FIG. 2.
Development of corneal erosions during
Staphylococcus keratitis in passively immunized rabbits and
control rabbits. Bacteria were mixed with either immune or preimmune
sera at a ratio of 1:1, and the corneas (n = 4) were
injected with 20 µl of the serum-bacteria mixture. Erosion score (A)
is based on coverage of the cornea and ranked between 0 and 4. Erosion
diameters (B) were visualized using fluorescein and measured with a
ruler. Both erosion scores and diameters were significantly smaller in
passively immunized eyes than in the eyes of control rabbits (treated
with preimmune sera) at 20 and 25 h p.i. Each asterisk denotes a
significant difference between groups treated with immune or preimmune
sera (P
0.041). Data are expressed as mean erosion
score/diameter ± SEM.
Active immunization with 2 to 4 injections of toxoid in CFA resulted in serum titers of 5,000 for either total antibody or IgG antibody. However, the IgA titer for alpha-toxin in tears was not substantially increased over that of the preimmune or control rabbits (titers = 300 ± 100).
Infection of rabbits actively immunized with alpha-toxin toxoid
resulted in significantly less pathology (by SLE score) throughout infection (10 to 25 h p.i.) than infection of control rabbits injected with CFA alone (P
0.0004) (Fig.
3). Epithelial erosions were not as
extensive in the corneas of immune rabbits compared to those in the
corneas of control rabbits from 17.5 h p.i. until time of
sacrifice (P
0.0001) (Fig.
4). There was no significant difference
in the numbers of bacteria (approximately 7 log CFU per cornea)
obtained from the corneas of immunized or control rabbits (P = 0.3061).
|
|
This study has shown, for the first time, that passive or active immunization to alpha-toxin protects the cornea from damage during Staphylococcus keratitis. These findings confirm the data from genetic studies (6, 21) and from histopathological studies (20) showing that alpha-toxin is largely responsible for the development of severe tissue damage and inflammation during keratitis. Passive immunization of infected individuals could be useful in limiting tissue damage, particularly in conjunction with antibiotic therapy. Active immunization for Staphylococcus infections has been extensively studied (1, 9-12, 15-19, 24) and, for those patients at risk, is a feasible proposition for controlling tissue damage. Vaccination is of increasing priority due to the broadening antibiotic resistance of Staphylococcus, including vancomycin resistance (13, 14, 22, 23, 27) and the emergence of methicillin-resistant S. aureus infections in the general population (7).
| |
ACKNOWLEDGMENTS |
|---|
We thank Kiana Nelson for her technical assistance.
This research was supported by NIH grant RO1 EY10974.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: The Department of Microbiology, Immunology, and Parasitology, LSU Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112. Phone: (504) 568-4072. Fax: (504) 568-2918. E-mail: rocall{at}lsumc.edu.
Editor: J. T. Barbieri
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Adlam, C.,
P. D. Ward,
A. C. McCartney,
J. P. Arbuthnott, and C. M. Thorley.
1977.
Effect of immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits.
Infect. Immun.
17:250-256 |
| 2. | Arvidson, S. O. 1983. Extracellular enzymes from Staphylococcus aureus, p. 745-808. In C. S. F. Easmon, and C. Adlam (ed.), Staphylococci and staphylococcal infections. Academic Press, London, England. |
| 3. |
Asbell, P., and S. Stenson.
1982.
Ulcerative keratitis: survey of 30 years' laboratory experience.
Arch. Ophthalmol.
100:77-80 |
| 4. | Bernheimer, A. W. 1988. Assay of hemolytic toxins. Methods Enzymol. 165:213-217[Medline]. |
| 5. | Blomqvist, L., and A. M. Sjogren. 1988. Production and characterization of monoclonal antibodies against Staphylococcus aureus alpha-toxin. Toxicon 26:265-273[Medline]. |
| 6. |
Callegan, M. C.,
L. S. Engel,
J. M. Hill, and R. J. O'Callaghan.
1994.
Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis.
Infect. Immun.
62:2478-2482 |
| 7. |
Centers for Disease Control and Prevention.
1999.
Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus Minnesota and North Dakota, 1997-1999.
Morb. Mortal. Wkly. Rep.
32:707-710.
|
| 8. |
Coia, J. E.,
L. Browning,
L. Haines,
T. H. Birkbeck, and D. J. Platt.
1992.
Comparison of enterotoxins and haemolysins produced by methicillin-resistant (MRSA) and sensitive (MSSA) Staphylococcus aureus.
J. Med. Microbiol.
36:164-174 |
| 9. | Fattom, A. I., J. Sarwar, A. Ortiz, and R. Naso. 1996. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64:1659-1665[Abstract]. |
| 10. | García, V. E., M. F. Iglesias, M. C. Cerquetti, M. I. Gómez, and D. O. Sordelli. 1994. Interaction between granulocytes and antibodies in the enhancement of lung defenses against Staphylococcus aureus after intranasal immunization with live-attenuated bacteria. FEMS Immunol. Med. Microbiol. 9:55-64[Medline]. |
| 11. |
Greenberg, D. P.,
J. I. Ward, and A. S. Bayer.
1987.
Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits.
Infect. Immun.
55:3030-3034 |
| 12. |
Greenberg, D. P.,
A. S. Bayer,
A. L. Cheung, and J. I. Ward.
1989.
Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model.
Infect. Immun.
57:1113-1118 |
| 13. | Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673[CrossRef][Medline]. |
| 13a. | Institute of Laboratory Animal Resources. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C. |
| 14. |
Kantzanou, M.,
P. T. Tassios,
A. Tseleni-Kotsovili,
N. J. Legakis, and A. C. Vatopoulos.
1999.
Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus.
J. Antimicrob. Chemother.
43:729-731 |
| 15. | Lee, J. C., J. S. Park, S. E. Shepherd, V. Carey, and A. Fattom. 1997. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 65:4146-4151[Abstract]. |
| 16. | Lowell, G. H., C. Colleton, D. Frost, R. W. Kaminski, M. Hughes, J. Hatch, C. Hooper, J. Estep, L. Pitt, M. Topper, R. E. Hunt, W. Baker, and W. B. Baze. 1996. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun. 64:4686-4693[Abstract]. |
| 17. | Lowell, G. H., R. W. Kaminski, S. Grate, R. Hunt, C. Charney, S. Zimmer, and C. Colleton. 1996. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun. 64:1706-1713[Abstract]. |
| 18. | Mamo, W., P. Jonsson, J. I. Flock, M. Lindberg, H. P. Müller, T. Wadström, and L. Nelson. 1994. Vaccination against Staphylococcus aureus mastitis: immunological response of mice vaccinated with fibronectin-binding protein (FnBP-A) to challenge with S. aureus. Vaccine 12:988-992[CrossRef][Medline]. |
| 19. |
McKenny, D.,
K. L. Pouliot,
Y. Wang,
V. Murthy,
M. Ulrich,
G. Döring,
J. C. Lee,
D. A. Goldmann, and G. B. Pier.
1999.
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.
Science
284:1523-1527 |
| 20. | Moreau, J. M., G. M. Sloop, L. S. Engel, J. M. Hill, and R. J. O'Callaghan. 1997. Histopathological studies of staphylococcal alpha-toxin: effects on rabbit corneas. Curr. Eye Res. 16:1221-1228[CrossRef][Medline]. |
| 21. | O'Callaghan, R. J., M. C. Callegan, J. M. Moreau, L. C. Green, T. J. Foster, O. M. Hartford, L. S. Engel, and J. M. Hill. 1997. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect. Immun. 65:1571-1578[Abstract]. |
| 22. | Peterson, D. L. 1999. Vancomycin-resistant Staphylococcus aureus. Infect. Med. 16:235-238. |
| 23. | Sanders, C. C., W. E. Sanders, Jr., and K. S. Thomson. 1995. Fluoroquinolone resistance in staphylococci: new challenges. Eur. J. Clin. Microbiol. Infect. Dis. 14(Suppl. 1):S6-S11. |
| 24. | Schennings, T., A. Heimdahl, K. Coster, and J. I. Flock. 1993. Immunization with fibronectin binding protein from Staphylococcus aureus protects against experimental endocarditis in rats. Microb. Pathog. 15:227-236[CrossRef][Medline]. |
| 25. | Seal, D., L. Ficker, M. Ramakrishnan, and P. Wright. 1990. Role of staphylococcal toxin production in blepharitis. Ophthalmology 97:1684-1688[Medline]. |
| 26. | Statistical Analysis Systems Institute. 1981. Statistical analysis systems for linear models: a guide to the ANOVA and GLM procedures. In R. J. Freund, and R. C. Little (ed.), SAS series in statistical applications. SAS Institute, Inc., Cary, N.C. |
| 27. | Wilhelmus, K. R., and R. L. Penland. 1996. Emerging resistance among ocular isolates of gram-positive cocci. Investig. Ophthalmol. Vis. Sci. 37(Suppl.):877. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»